Last reviewed · How we verify
Tafluprost 15µg/ml
Tafluprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
Tafluprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Tafluprost 15µg/ml |
|---|---|
| Sponsor | Ordination Dr. Hommer |
| Drug class | Prostaglandin F receptor agonist |
| Target | FP receptor (prostaglandin F receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tafluprost binds to prostaglandin F receptors in the eye, primarily enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This increased outflow reduces intraocular pressure, which is the primary pathogenic factor in glaucoma and ocular hypertension. The drug is administered as an ophthalmic solution directly to the affected eye.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Increased iris pigmentation
- Eyelash growth (hypertrichosis)
- Foreign body sensation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafluprost 15µg/ml CI brief — competitive landscape report
- Tafluprost 15µg/ml updates RSS · CI watch RSS
- Ordination Dr. Hommer portfolio CI